Stryker stock jumps over 4% as investors respond to operational turnaround plans

Traders Union
All News
Stocks
Stryker rises 4.33% today after earnings

Highlights

Stryker reported third quarter 2026 sales of $6.52 billion with 7.6% to 7.7% organic growth, missing both revenue and adjusted EPS estimates.
The company lowered full-year adjusted EPS guidance to $14.80 to $14.90 and reported margin pressure, citing weaker demand for hip and knee procedures, supply issues, SAP transition challenges, and cyber incident effects.
Shares of Stryker are trading near session highs with mixed technical indicators and are expected to consolidate between $289.63 and $319.09 in the next five sessions, with a high probability of a move lower.

Guidance cut and margin decline as procedures, supply, and SAP weigh

Stryker reported third quarter 2026 sales of $6.52 billion, representing 7.6-7.7% year-on-year organic growth, but both revenue and adjusted earnings per share of $3.52 missed expectations. The company lowered its full-year adjusted EPS guidance to $14.80–$14.90, citing softer demand for hip and knee replacement procedures, ongoing supply issues in peripheral vascular products, execution challenges from a recent SAP transition, and residual effects from a prior cyber incident. Stryker also recorded a $293 million goodwill impairment and noted operational margin pressure, with operating margin falling to 15.9% from 18.7% the previous year. New product launches including Mako RPS and Sonopet 3, along with ongoing efforts to restore supply chains and improve commercial execution, accompanied several institutional portfolio adjustments during the period.

Anton Kharitonov, expert at Traders Union, sees Stryker's recent rebound as short-lived. The analyst notes missed earnings, margin contraction, and guidance cuts as fundamental red flags. He points to persistent operational and supply chain risks, alongside a bearish medium-term trend. Technical indicators show conflicting signals, with resistance capping further gains. "Despite today's pop, structural weaknesses suggest traders should remain wary of false breakouts and protect capital here," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, highlights Stryker’s resilience and forward-looking strategy. He emphasizes renewed buying interest after the company outlined solid steps to fix operational issues. Karapetjanc finds the strong organic growth and upcoming product launches supportive for long-term prospects. He believes the current technical setup offers multiple opportunities for trend re-entry. "The bullish structure remains intact — further growth is likely as operational fixes and new products take hold," Karapetjanc states.

Sholanke Dele, market strategist, remains cautious on Stryker. He sees margin pressure and a recent goodwill impairment as major warning signs. Dele highlights the lack of clear momentum and a weak medium-term trend. "I do not expect upside unless Stryker quickly resolves supply and execution issues — near-term volatility signals risk for new buyers," says Dele.

Mixed momentum and overbought risk as price nears long-term ceiling

Stryker is trading above both its 20-day and 50-day moving averages ($292.92 and $292.76), indicating near-term strength, but remains below the 200-day moving average ($323.83), which highlights lingering long-term resistance. The Ichimoku Kijun at $291.44 provides a layer of support, with the next near-term ceiling at $312.56 and the floor set by today's high at $298.94. Medium-term trend alignment remains bearish. Momentum signals are mixed, with the Moving Average Convergence Divergence (MACD) pointing to bullish momentum, the Average Directional Index (ADX) at 18.3 suggesting a weak trend, and the Relative Strength Index (RSI) at 47.94 showing a sell signal. The Stochastic RSI at 5.03 indicates an oversold condition. The Commodity Channel Index (CCI) is neutral, and Bull/Bear Power (BBP) at 0.5 shows buyers are dominating, but with an overbought alert. Intraday volatility stands at 5.60%, and the price is near the session high, showing strength toward highs despite conflicting oscillator signals.

Earlier, analysts noted that Stryker's technical setup showed strong short-term momentum but flagged key long-term resistance amid neutral indicator readings. The latest earnings and mixed technicals now reinforce a cautious outlook, with a decisive move above $312.56 required to shift the prevailing medium-term bearish trend.

Source of Data: SYK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.